伴弥漫大B细胞淋巴瘤基因表达特征的高级别B细胞淋巴瘤非特指型:基因组分析与潜在治疗靶点
研究纳入55例高级别B细胞淋巴瘤非特指型(HGBCL, NOS)患者(成人45例,儿童10例),比较其基因表达谱、DNA拷贝数和突变谱与85例原发DLBCL及52例BL。该亚组约占HGBCL, NOS的60%,缺乏BL及双打击/暗区淋巴瘤表达特征,而表达DLBCL样特征,基因组复杂性与原发DLBCL相似。体外抑制PIM1可触发B细胞活化及NF-κB诱导的凋亡,提示PIM1为合理治疗靶点。
要点
- 约60%的HGBCL, NOS缺乏BL及双打击/暗区淋巴瘤表达特征,而表达GCB或ABC样DLBCL特征。
- 该亚组基因组复杂性与原发DLBCL相似,但携带DDX3X、GNA13、CCND3等BL常见而DLBCL少见的突变。
- 成人HGBCL, NOS频发PIM1致癌突变,体外抑制PIM1可触发B细胞活化及NF-κB诱导的凋亡。
核心结论
- 伴DLBCL基因表达特征的HGBCL, NOS亚组具有独特的基因组和突变谱,PIM1可能为其合理治疗靶点。
研究设计与样本
- 研究纳入55例HGBCL, NOS患者(成人45例,儿童10例),比较其基因表达谱、基因组DNA拷贝数和突变谱与85例原发DLBCL及52例BL。
主要发现
- 该亚组约占HGBCL, NOS的60%,缺乏BL及双打击/暗区淋巴瘤基因表达特征,而表达DLBCL样特征及GCB或ABC样mRNA特征。
- 该亚组基因组复杂性与原发DLBCL相似,并携带B细胞活化(CD79B、MYD88、PRDM1、TBLIXR1、CARD11)、表观基因组(KMT2D、TET2)及细胞周期转换(TP53、ASPM)相关基因改变。
- 该亚组还携带BL常见而DLBCL少见的DDX3X、GNA13、CCND3 recurrent突变,提示遗传异质性。
- 基因组拷贝数改变包括B细胞活化相关基因(del-PRDM1、gain-BCL6、-REL、-STAT3)及细胞周期调控基因(del-TP53、del-CDKN2A、del-RB1、gain-CCND3)频发改变。
- 儿童病例呈GCB-DLBCL样mRNA特征,但也具有儿童BL的标志性突变;成人HGBCL, NOS频发PIM1致癌突变。
关键数值与推荐
- 体外药物或遗传抑制PIM1表达可触发B细胞活化及NF-κB诱导的凋亡,提示PIM1为合理治疗靶点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-grade B-cell lymphoma not otherwise specified (HGBCL, NOS) has overlapping morphological and genetic features with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), leading to uncertainty in its diagnosis and clinical management. Using functional genomic approaches, we previously characterized HGBCL and NOS, that demonstrate gene expression profiling (GEP), and genetic signatures similar to BL. Herein, we characterize distinct HGBCL, NOS, cohort (n = 55) in adults (n = 45) and in children (n = 10), and compared the GEP, genomic DNA copy number (CN), and mutational spectrum with de novo DLBCL (n = 85) and BL (n = 52). This subgroup, representing ~60% of HGBCL, NOS, lack gene-expression signature of BL and double hit/dark zone lymphoma, but express DLBCL like signatures and are characterized by either GCB- or ABC-like mRNA signatures and exhibit higher genomic complexity, similar to de novo DLBCL, and show alteration in genes regulating B-cell activation (CD79B, MYD88, PRDM1, TBLIXR1, CARD11), epigenome (KMT2D, TET2) and cell cycle transition (TP53, ASPM). However, recurrent mutations in genes often mutated in BL (DDX3X, GNA13, CCND3), but rare in DLBCL, are also present in HGBCL-NOS, highlighting genetic heterogeneity. Consistent with mutation spectrum, frequent genomic CN alterations in genes regulating B-cell activation (del-PRDM1, gain-BCL6, -REL, -STAT3) and cell cycle regulators (del-TP53, del-CDKN2A, del-RB1, gain-CCND3) were observed. Pediatric cases showed GCB-DLBCL-like mRNA signatures, but also featured hallmark mutations of pediatric BL. Frequent oncogenic PIM1 mutations were present in adult HGBCL, NOS. In vitro analyses with pharmacologic or genetic inhibition of PIM1 expression triggered B-cell activation and NF-κB-induced apoptosis, suggesting that PIM1 is a rational therapeutic target.
引用
- Lone W, Bouska A, Herek TA, et al. High-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures: Genomic analysis and potential therapeutics. Am J Hematol. 2024. PMID: 39548807. doi:10.1002/ajh.27513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。